Key Takeaways
- 52% YoY revenue surge, broad-based: Total income jumped 52% YoY in Q3, driven by deeper customer engagement, geographic expansion, and strong specialty ingredient momentum.
- Battery materials is now a real, de-risked pipeline: 34 customers engaged, ~70% have validated samples, commercial scale-up orders are in hand, and off-take agreements are under active negotiation, all ahead of the Dahej facility coming online in early 2027.
- The US tariff story is a net positive: Management passed 90% of tariff impact to customers with no margin dilution, and sees India as one of the most competitive nations in a trade deal scenario, setting up FY27 for significant North American revenue and margin expansion.
- Margins held steady despite investment: 9M EBITDA margin dipped 150 bps to 37.6% with no single cause cited, while the NSS acquisition was quickly brought to Sudeep's margin profile and the greenfield pharma facility nears commissioning.
- What to watch next quarter: Q4 is historically the strongest quarter, so the sequential step-up will test whether the 52% growth rate is sustainable; also watch for initial revenue contribution from the Nandesari greenfield facility and any named off-take agreement announcements.
The Battery Materials Bet Is De-Risking Rapidly
- Customer funnel is deep and advancing: 34 customers span the battery value chain across North America, South Korea, Japan, and Indonesia; ~70% have approved or validated samples, with the remainder optimizing for specific requirements.
- Commercial orders have begun: Scale-up orders are already received from customers moving from analysis to large-scale pilot testing, and multiple facility visits from global OEM, cell, and cathode manufacturers occurred this quarter.
- Off-take agreements in active negotiation: Discussions underway with large OEMs and cell manufacturers; details remain confidential under NDAs, but the direction is toward binding commitments.
- China-plus-one positioning is the wedge: Sudeep is the first company globally to offer an ex-China source of battery-grade iron phosphate, a claim that resonates strongly with customers navigating regulatory requirements in critical markets.
- China's VAT rebate elimination adds tailwind: The removal has already driven a 15-20% price increase from Chinese suppliers for iron phosphate; while cost is not the primary criterion today, it reinforces Sudeep's narrative with customers.
- Green chemistry as a moat: Proprietary technology is claimed to be significantly more efficient than Chinese processes on both environmental and operating cost dimensions, with electrochemical performance described as at par, if not better, than incumbent Chinese vendors.
Shanil Bhayani: "I think how we are positioning Sudeep is an alternative to China to support customers kind of fulfill the regulatory requirements in critical markets."
Core Nutrition Business: Volume-Led, Geography-Widening
- Calcium is the entry wedge: The portfolio is central to the business as a volume driver and platform for customer entry and cross-selling; CEP certification for calcium carbonate (the only Indian company, one of nine globally) reduces entry barriers in regulated markets.
- Magnesium and iron portfolios gaining momentum: Rising consumer awareness and demand for targeted health benefits are shifting supplement preferences toward these minerals.
- Asia-Pacific is the breakout region: Growth driven by deeper collaboration with leading FMCG and infant nutrition customers, with increasing repeat business and wider product adoption.
- Europe is emerging as a meaningful market: A dedicated sales team is now fully operational; multiple products are already approved with additional approvals underway, delivering strong sequential growth.
- India delivered nearly 20% growth: Consistent demand and long-standing customer relationships supported the domestic market.
- The world's largest packaged goods company is deepening ties: Expanded sourcing from Sudeep to additional geographies including Brazil and India, on top of the existing US relationship, signaling increasing wallet share.
Specialty Ingredients: The Growth Engine Firing
- Encapsulated and premixed product lines delivered strong growth: Customer engagement is deepening, and critical approvals came through this quarter.
- Tortilla win opens a new vertical: Initiated business with a global leader in tortilla manufacturing; the encapsulated ingredient extends shelf life and provides an alternative to an American supplier.
- Infant nutrition premix approval secured: Received approval from a leading infant nutrition company to supply a blend of vitamins and minerals, a high-barrier, sticky category.
- Utilization headroom is substantial: The specialty ingredients segment is running at only 35-40% utilization, so no significant capex is needed to capture the next leg of growth.
- Growth trajectory is durable: Management expects the 30-35% growth momentum to continue over the next two years as approvals convert to revenue.
Liposomal Platform: The Next Pipeline
- Indigenous technology, now clinically validated: The liposomal platform was built in-house; two products (liposomal iron and vitamin C) have completed clinical studies showing 80% higher absorption versus regular iron.
- Pipeline is broadening beyond iron: Capabilities are expanding to other nutrients including vitamins, DHA for brain health, and glutathione for cosmeceutical applications.
- Revenue timeline is back-end loaded: Active engagement spans India, North America, Europe, and the Middle East, but meaningful revenue contribution is expected only from H2 FY27, and more significantly in FY28.
Shanil Bhayani: "We will start to see a revenue contribution from this maybe in H2 FY '27 and more significantly in FY28, as we have just completed our clinical studies on these two products."
Margins, Tariffs & the US Opportunity
- 9M EBITDA margin dipped 150 bps to 37.6%: No single reason was isolated; the decline sits against a backdrop of investment in sales teams, the NSS integration, and the greenfield build-out.
- NSS margin profile already normalized: Since the May acquisition, management optimized the raw material supply chain and began supplying products from Sudeep; the margin profile is now similar to Sudeep's own.
- US tariffs were a pass-through, not a hit: Across at least 90% of the business where tariffs were effective, the impact was passed on to the customer with no margin dilution.
- A trade deal could make India the winner: Management believes India will be one of the most competitive nations from a tariff perspective; with a deal, the project pipeline is expected to strengthen materially, and FY27 North America should see significant revenue, growth, and margin expansion.
Shanil Bhayani: "We have not taken a margin hit or margin dilution by accepting the tariff impact. Majority, I would say, maybe at least across 90% of the business where tariff was effective, we have passed on the tariff impact to the customer."
Capacity Build-Out: Phased and Demand-Linked
- Nandesari greenfield pharma facility on track: Commissioning is set for Q4 FY26 (March 2026); H2 FY27 will see initial customer servicing from the site, with a more significant ramp in FY28 after Q1-Q2 site approvals from key customers.
- New molecules will lift the margin profile long term: At least 50% of the greenfield capacity is for core products (carbonates, phosphates); the remaining 50% is for newer molecules like gluconates and glycinates, which face limited global competition and carry stronger margins.
- Dahej battery materials facility broke ground: Phase 1 (25,000 MTPA) is on track for early 2027 commissioning; the site includes land for the full 100,000-ton facility, with sequential scale-up from 25 to 50, and potentially 50 directly to 100, depending on off-take agreements.
- Battery capex is ~₹300 cr for Phase 1: This includes land for the entire facility; financing is primarily through internal accruals, with no significant interest impact expected.
- Core business needs no major capex beyond Nandesari: Existing capacity is sufficient to grow, and specialty ingredients have ample headroom at current utilization.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Nandesari greenfield commissioning | Facility on track for commissioning | Q4 FY26 (March 2026) |
| Nandesari utilization ramp | Scale to 30-40% utilization, then ramp further | FY28 onwards |
| Dahej Phase 1 commissioning | 25,000 MTPA battery-grade iron phosphate capacity | Early 2027 |
| Battery materials revenue contribution | First revenue from battery materials | FY28 |
| Battery materials asset turns | Approximately 3x, similar to core business | At commercialization |
| Liposomal revenue contribution | Initial revenue expected | H2 FY27, more significantly in FY28 |
| Specialty ingredients growth rate | 30-35% growth momentum to continue | Next two years |
| NSS growth rate | ~15% organic growth plus Sudeep-led project upside | Next one to two years |
| Overall margin profile | Maintain historically maintained levels, no significant change | FY27 |
| US tariff impact on margins | No margin dilution; 90%+ passed through to customers | Current, ongoing |
| Battery materials depreciation | Depreciation begins only when revenue starts | FY28 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Total income | ₹179.2 cr, +52% YoY vs ₹118 cr in Q3 FY25 |
| EBITDA | ₹66.8 cr, +60% YoY vs ₹41.7 cr in Q3 FY25 |
| EBITDA margin | 37.3% |
| PAT | ₹47.7 cr, +66% YoY vs ₹28.7 cr in Q3 FY25 |
| Total income (9M FY26) | ₹482.1 cr, +38% YoY vs ₹350 cr in 9M FY25 |
| EBITDA margin (9M FY26) | 37.6% vs 39.1% in 9M FY25 |
| Revenue excluding NSS | ₹156 cr for Q3, +35.26% YoY (per an analyst's math) |
| Revenue excluding NSS (9M FY26) | ₹416 cr, +21% YoY (per an analyst's math) |
| Export contribution | 62% of total income; domestic contributed 38% |
| Specialty business contribution | 41% of total income; pharma, food and nutrition contributed 59% |
| India domestic market growth | nearly 20% in Q3 |
| Networking capital days | ~180 days |
| Nandesari Greenfield facility capacity | 51,200 metric tons, commissioning March 2026 |
| Battery-grade iron phosphate capacity addition | 5,000 tons at existing facilities |
| Battery materials Phase 1 capex | approximately ₹300 cr, includes land for entire 100,000 ton facility |
| Total capex for 100,000 ton battery facility | approximately ₹550 cr to ₹600 cr |
| Specialty ingredients capacity utilization | close to 40% |
| Pharma food nutrition capacity utilization | around 65% to 70% |
| NSS contribution | ₹17-odd cr of revenue |
| Battery materials customer engagements | 34 customers across the battery value chain |
| Battery materials customer approvals | ~70% of 34 customers have approved and validated samples |
| US business tariff exposure | 50% of US business was subject to tariff; tariff impact passed on to customer across at least 90% of that business |